Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2021-08-23 00:00:00 ET · period of report 2021-08-19 · accession 0001714899-21-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-08-23 | 2021-08-19 | DNLI | Krognes Steve E. | CFO, Treas | S - Sale | $49.57 | -2,285 | 95.3K | -2% | -$113.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-19 | S | D | 2,085 | $49.52 | 95,502 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.00 to $49.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 75,358 restricted stock units. |
| 2 | Common | Common Stock | 2021-08-19 | S | D | 200 | $50.07 | 95,302 | D | — | — | (F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.04 to $50.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 75,358 restricted stock units. |